Vermont
Fee-For-Service Medicaid Coverage of Screening
Covered
Highlighted Disparity
No racial disparities were found in Vermont for these lung cancer metrics.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 56.4 and not significantly different than the national rate of 54.6.
- Vermont ranks 25th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases improved by 26%.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Vermont is 30.6%, which is significantly higher than the national rate of 26.6%.
- It ranks 5th among the 42 states with survival data, placing it in the top tier.
- Over the last five years, the survival rate in Vermont improved by 33%.
Early Diagnosis:
- 30.3% of cases are caught at an early stage, which is significantly higher than the national rate of 26.6%.
- It ranks 5th among the 47 states with data on diagnosis at an early stage, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in Vermont improved by 30%.
Lung Cancer Treatment
Surgical Treatment:
- Vermont ranked 26th (out of the 47 states with available data) with 19.5% of cases undergoing surgery as part of the first course of treatment.
- This is not significantly different than the national rate of 20.8% and puts Vermont in the average tier.
- Over the last five years, the percent of cases undergoing surgery in Vermont did not change significantly.
Lack of Treatment:
- Vermont ranked 32nd (out of the 47 states with available data) with 21.3% of cases not receiving any treatment.
- This is not significantly different than the national rate of 20.6% and puts Vermont in the average tier.
- Over the last five years, the percent of cases receiving no treatment in Vermont did not change significantly.
Screening
Screening for High Risk:
- In Vermont, 10.0% of those at high risk were screened, which was significantly higher than the national rate of 4.5%.
- It ranks 4th among all states, placing it in the top tier.
- Actual screening rates may be higher in states with large, regional managed care providers that did not share screening data.
Medicaid Coverage:
- Vermont was one of the 49 states whose Medicaid fee-for-service programs covered lung cancer screening as of October 2023.
- While their program did not require prior authorization or copays, it did not use recommended guidelines for determining eligibility.
Prevention
Tobacco Use:
- The smoking rate in Vermont is 14.8% and not significantly different than the national rate of 13.5%.
- It ranks 30th among all states, placing it in the average tier.
Radon:
- In Vermont, 21.7% of radon tests results were at or above the action level recommended by EPA.
- It ranks 24th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- Lung cancer rates are not available for Black individuals in Vermont due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- Lung cancer rates are not available for Latino individuals in Vermont due to too few cases over the time period to allow for accurate analysis.
Asian Americans or Pacific Islanders:
- Lung cancer rates are not available for Asian or Pacific Islander individuals in Vermont due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Vermont due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Vermont falling into the above average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
The Lung Association encourages all states to cover lung cancer screening based on the latest guidelines across all fee-for-service and managed care plans without any financial or administrative barriers in their Medicaid programs.
Vermont falls into the average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.